PT  - JOURNAL ARTICLE
AU  - Cristiano Rodrigo Alvarenga-Nascimento
AU  - Auriléia Aparecida De Brito Léia
AU  - Tawany Gonçalves Santos
AU  - Karine Zanela Herculano
AU  - Stephanie Soares
AU  - Renata Kelly Da Palma
AU  - Ana Paula Ligeiro-Oliveira
TI  - Photobiomodulation acting as an immunotherapeutic strategy for chronic obstructive diseases such as asthma and COPD
AID  - 10.1183/13993003.congress-2020.2056
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 2056
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/2056.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/2056.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Photobiomodulation (PBM), can be used in lung diseases, due to the low cost and absence of effects. This therapy aims at a negative policy of cytokines, chemokines and transcription factors. It is known that Treg lymphocytes suppress other effector cells (Th1, Th2 and Th17) and inflammatory cells for tissues, as well as the release of inflammatory mediators. In this sense, the objective was to evaluate Foxp3 Treg cells, as well as the production of IL10 in the lung after PBM in obstructive diseases such as asthma and COPD. Some parameters were studied in Balb/C with asthma and C57BL/6 with COPD submitted to the diode laser (660nm, 100mW, 180s) for 15 days. The protocol used for asthma induction consisted of sensitization with ovalbumin (day 0 and day 14) and orotracheal challenge on day 21 (3x per week/5 weeks) and that of COPD in the application of extract from the cigarette smoke orotracheal pathway (3x per week/7 weeks). Bronchoalveolar lavage (BAL) and lungs were collected for analysis. The data were submitted to the One-way ANOVA test followed by the Newman-Keuls test. Significance levels adjusted to 5% (p<0.05). PBM reduced the number of inflammatory cells, the levels of IL1-β, TNF-α, IL-6, IFN-γ, (p<0,001), LTB4 (p<0,01), IL-5 and IL-4 in asthma (p<0,001), and increased IL-10 (p<0,001). We also observed a decrease in collagen and mucus (p<0,001). there was a significant increase CD4+CD25+Foxp3+ and CD4+IL-10+. Thus, PBM can be used as an immunotherapeutic strategy for the treatment of these diseases through the possible mechanism of CD4+CD25+Foxp3+ and CD4+IL-10+ modulating inflammation.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2056.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).